97109 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses; Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus Varicella-zoster virus, e.g. cytomegalovirus
Herpes Zoster Treatment
#2THERAPEUTIC POLYNUCLEOTIDES ENCODING T CELL RECEPTOR (TCR) ALPHA CHAIN POLYPEPTIDES AND/OR TCR BETA CHAIN POLYPEPTIDES
#3MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES
#4DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS
#5ANTI-VARICELLA-ZOSTER VIRUS ANTIBODY AND USE THEREOF
#6T CELL ANTIGEN RECEPTOR, MULTIMERIC COMPLEX THEREOF AND PREPARATION METHOD AND USE THEREOF
#7Methods and compositions comprising purified recombinant polypeptides
#8SYSTEMS AND METHODS TO PRODUCE B CELLS GENETICALLY MODIFIED TO EXPRESS SELECTED ANTIBODIES
#9Anti-Varicella-Zoster Virus Antibody
#10ANTIBODIES
#11ANTIBODY AGAINST HUMAN CYTOMEGALOVIRUS AND USE THEREOF
#12T CELL EPITOPES OF HCMV AND USES OF THEREOF
#13Identification and Elimination of HCMV-Infected Cells
#14MHC class I epitope delivering polypeptides
#15SIV AND HIV VACCINATION USING RHCMV- AND HCMV-BASED VACCINE VECTORS
#16De-immunized Shiga toxin a subunit effector polypeptides for applications in mammals
#17MANIPULATION OF IMMUNOGLOBULIN GENE DIVERSITY AND MULTI-ANTIBODY THERAPEUTICS
#18SIV AND HIV VACCINATION USING RHCMV- AND HCMV-BASED VACCINE VECTORS
#19Anti-varicella-zoster virus antibody, immunological measurement method, and immunological measurement device
#20HUMAN iPSC-DERIVED BRAIN ORGANOIDS AND USES THEREOF
#21MHC class I epitope delivering polypeptides
#22Systems and methods to produce B cells genetically modified to express selected antibodies
#23Methods of purifying recombinant anti-abeta antibodies
#24HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
#25CELL-TARGETING MOLECULES COMPRISING PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CARBOXY-TERMINAL MOIETIES
#26Broadly neutralizing anti-human cytomegalovirus (HCMV) antibodies and methods of use thereof
#27MVA-gH/gL-PC vaccine derived antibodies neutralizing human cytomegalovirus infectivity and methods thereof
#28Passive antibody dependent cell-mediated activation
#29Human cytomegalovirus neutralizing antibodies and use thereof
#30Cytomegalovirus surface protein complex for use in vaccines and as a drug target
#31Specific binding agents to varicella-zoster virus and uses related thereto
#32MHC Class I Epitope Delivering Polypeptides
#33CMV neutralizing antigen binding proteins
#34Human cytomegalovirus neutralizing antibodies and use thereof
#35METHODS AND COMPOSITIONS FOR THE TREATMENT OF HCMV
#36Compositions comprising purified anti-abeta monoclonal antibodies
#37Methods and compositions comprising purified recombinant polypeptides
#38Compositions comprising purified recombinant IL-13 antibody
#39Method of treatment comprising purified recombinant IL-13 antibody
#40MVA-gh/gL-PC vaccine derived antibodies neutralizing human cytomegalovirus infectivity and methods thereof
#41Human cytomegalovirus neutralizing antibodies and use thereof
#42ANTIBODIES, VARIABLE DOMAINS & CHAINS TAILORED FOR HUMAN USE
#43Human cytomegalovirus neutralizing antibodies and use thereof
#44COMBINATION OF HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES
#45High affinity human antibodies to human cytomegalovirus (CMV) gB protein
#46Human cytomegalovirus neutralizing antibodies and use thereof
#47Human cytomegalovirus neutralizing antibodies and use thereof
#48Cell-targeting molecules comprising protease-cleavage resistant, Shiga toxin A subunit effector polypeptides and carboxy-terminal moieties
#49Human cytomegalovirus neutralizing antibodies and use thereof
#50DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS
#51Methods and compositions comprising purified recombinant polypeptides
#52METHODS AND COMPOSITIONS FOR THE TREATMENT OF HCMV
#53Human cytomegalovirus neutralising antibodies and use thereof
#54Human cytomegalovirus neutralizing antibodies and use thereof
#55Human cytomegalovirus neutralizing antibodies and use thereof
#56CELL-TARGETED MOLECULES COMPRISING AMINO-TERMINUS PROXIMAL OR AMINO-TERMINAL SHIGA TOXIN A SUBUNIT EFFECTOR REGIONS
#57Human cytomegalovirus neutralizing antibodies and use thereof
#58CMV neutralizing antigen binding proteins
#59Human cytomegalovirus neutralizing antibodies and use thereof
#60ANTIBODY COMPOSITIONS AND METHODS OF USE
#61Human cytomegalovirus neutralizing antibodies and use thereof
#62High affinity human antibodies to human cytomegalovirus (CMV) GB protein
#63COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF CYTOMEGALOVIRUS INFECTIONS
#64Polyclonal bispecific antibody compositions and method of use
#65NERVE ELONGATION PROMOTER AND ELONGATION INHIBITOR
#66COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF CYTOMEGALOVIRUS
#67Anti-Human Cytomegalovirus Antibodies And Use Thereof
#68ANTIBODIES AND THEIR USES FOR DIAGNOSIS AND TREATMENT OF CYTOMEGALOVIRUS INFECTION AND ASSOCIATED DISEASES
#69Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
#70Human cytomegalovirus neutralizing antibodies and use thereof
#71Human cytomegalovirus neutralizing antibodies and use thereof
#72Methods and compositions for cytomegalovirus IL-10 protein
#73Human cytomegalovirus neutralising antibodies and use thereof
#74Human cytomegalovirus neutralizing antibodies and use thereof
#75Idiotypic antibodies and uses thereof
#76Intravenous Cytomegalovirus Human Immune Globulin and Manufacturing Method Thereof
#77Human cytomegalovirus neutralising antibodies and use thereof
#78HUMAN CYTOMEGALOVIRUS VACCINE
#79ANTIBODIES AND THEIR USES FOR DIAGNOSIS AND TREATMENT OF CYTOMEGALOVIRUS INFECTION AND ASSOCIATED DISEASES
#80Binding members for human cytomegalovirus
#81Human cytomegalovirus neutralizing antibodies and use thereof
#82Polyclonal bispecific antibody compositions and method of use
#83Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
#84Cytomegalovirus surface protein complex for use in vaccines and as a drug target
#85Human cytomegalovirus neutralizing antibodies and use thereof
#86Human cytomegalovirus neutralizing antibodies and use thereof
#87Monoclonal antibody capable of binding to specific discontinuous epitope occurring in AD1 region of human cytomegalovirus GB glycoprotein, and antigen-binding fragment thereof
#88ANTIBODY COMPOSITIONS AND METHODS OF USE
#89Human cytomegalovirus neutralising antibodies and use thereof
#90Human cytomegalovirus neutralising antibodies and use thereof
#91High affinity human antibodies to human cytomegalovirus (CMV) gB protein
#92Antibody composition with altered Fab sialylation
#93Compositions and methods for the therapy and diagnosis of cytomegalovirus
#94Human cytomegalovirus neutralizing antibodies and use thereof
#95Cytomegalovirus surface protein complex for use in vaccines and as a drug target
#96Antibodies Against Human Cytomegalovirus (HCMV)
#97Cytomegalovirus disintegrin-like peptides
#98Antibodies against human cytomegalovirus (HCMV)
#99Antibodies and their uses for diagnosis and treatment of cytomegalovirus infection and associated diseases
#100Human cytomegalovirus neutralizing antibodies and use thereof
#101Antibodies Specific for Varicella Zoster Virus
#102NERVE ELONGATION PROMOTER AND ELONGATION INHIBITOR
#103Antibodies against human cytimegalovirus (HCMV)
#104Compositions and methods for the therapy and diagnosis of cytomegalovirus
#105Anti-human cytomegalovirus antibodies
#106Human cytomegalovirus neutralising antibodies and use thereof
#107Human monoclonal antibody binding to human cytomegalovirus and its antigen binding portion
#108Human cytomegalovirus neutralizing antibodies and use thereof
#109Siv and Hiv Vaccination Using Rhcmv- and Hcmv-Based Vaccine Vectors
#110Cytomegalovirus surface protein complex for use in vaccines and as a drug target
#111Humanized immunoglobulins
#112Method for producing an in vitro expression library
#113Cytomegalovirus disintegrin-like peptides